Simultaneous Treatment of Moderate to Severe Horizontal Frontalis Lines, Glabellar Lines, and Lateral Canthal Lines With OnabotulinumtoxinA From the Subject's Perspective: Patient-Reported Satisfaction and Impact Outcomes From a Phase 3 Double-Blind Study

Steven Dayan, MD1; Patricia Ogilvie, MD, PhD2; Alexander Z. Rivkin, MD3; Steven G. Yoelin, MD4; Julie K. Garcia, PhD5; Ilia L. Ferrusi, PhD5

1DeNova Research, Chicago, IL; 2SkinConcept, Munich, Germany; 3David Geffen School of Medicine, UCLA, Los Angeles, CA; 4Medical Associates Inc., Newport Beach, CA; 4Allergan plc, Irvine, CA

INTRODUCTION

- Upper facial lines (UFL) can negatively influence self-perception and have adverse psychological impacts1-3
- Subject satisfaction with aesthetic treatment reflects successful treatment outcomes, which in turn may be associated with improved self-esteem and body image! · OnabotulinumtoxinA has been used effectively and safely to treat facial lines since the
- When treating forehead lines (EHL) concurrent treatment of glabellar lines (GL) is When treating forestead lines (FHL), concurrent treatment originalear lines (LL), is recommended to reduce risk of eyebrow plosis by maintaining a balance between eyebrow elevator muscles (primarily the frontalis muscle) and depressor muscles (including the procerus and corrugator muscles making up the glabellar complex)⁴
- Clinical studies further support the use of onabotulinumtoxinA for treatment of UFL. with FHL treatment administered concurrently with treatment for GL and crow's fee
- The safety and efficacy of onabotulinumtoxinA for treating FHL and GL (40 U total) or FHL and GL with simultaneous treatment of CFL (64 U total) was evaluated in a 12-month phase 3 study^o
- The primary endpoint was met (proportion of subjects achieving ≥2-grade improvement from baseline in investigator and subject Facial Wrinkle Scale with Photonumeric Guide [FWS] scores of FHL severity at maximum eyebrow elevation 53.0% with onabotulinumtoxinA 64 U and 45.6% with onabotulinumtoxinA 40 U vs 0.6% with placebo on day 30; both P<0.0001)

OBJECTIVE

To present results from a 12-month, phase 3 study on the effects of onabotulinumtoxinA.

METHODS

Patients

- Neurotoxin-naive males and females aged ≥18 years with:
- Moderate to severe FHL at maximum eyebrow elevation (as assessed by both investigator and subject using the FWS on study day 1 prior to treatment)
- Moderate to severe GL at maximum frown (as assessed by the investigator on the FWS on study day 1)

 Moderate to severe bilaterally symmetrical CFL at maximum smile (as assessed by
- the investigator on the FWS on study day 1)

Study Design

- This 12-month phase 3 study was conducted at 10 sites in the United States and 14 sites in Europe from October 2014 to April 2016
- The study included a 6-month, double-blind, placebo-controlled, parallel-group treatment period (days 1–180) followed by a 6-month open-label treatment period (days 180–360) (Figure 1)



- Eligible subjects were randomized (2:2:1) to receive one of the following treatments
- OnabotulinumtoxinA 40 U (20 U in FHL, 20 U in GL, and placebo in CFL)

- OnabotulinumtoxinA 4 U or placebo was given as 0.1 mL at 16 injection sites (Figure 2)
- Onlabdullintimixin 4 0 or placetor was given as 0.1 life. at 1 on injection sites (Figure 4 or Following the double-blind period, subjects entered the open-label treatment period, during which they could receive up to 2 onabotulinumtoxin 64 U treatments using the same 16-injection site paradigm, with at least 84 days separating treatment cycles
- Follow-up assessments were made at weeks 1 and 2 after each study treatment: all subjects also had follow-up visits every 30 days starting on study day 30 though day 360

Figure 2. Injection Sites for Treatment of Forehead Lines, Glabellar Lines, and Crow's Feet Lines



Patient-Reported Outcome (PRO) Measures

- Subjects completed the Facial Line Satisfaction Questionnaire (FLSQ) and the 11-item Facial Line Outcomes Questionnaire (FLO-11) at baseline, on days 7, 14, and 30, then every 30 days through day 360
- Both PRO instruments were developed, validated, and implemented in accordance with US Food and Drug Administration guidance 10,11 FLSQ (11 questions at baseline and 13 questions at follow-up) is designed to assess
- reatment satisfaction and appearance-related impacts associated with facial lines in the FHL, GL, and/or CFL areas from the subject's perspective
- FLSQ Item 5 assesses the subjects' satisfaction with treatment of their facial lines FLSQ Impact Domain measures appearance-related and emotional impacts
- of treatment, including appearance-related age, anger, tiredness, emotional unhappiness, and negative self-esteem
- FLO-11 assesses psychological and appearance-related impacts associated with facial lines in the forehead, glabellar, and crow's feet areas, from the subjects' perspective
- FLO-11 Item 4 evaluates whether subjects feel that they look older than their actual age

Statistical Analysis

- FLSQ Item 5, FLSQ Impact Domain, and FLO-11 Item 4 were included as key secondary efficacy endpoints as they reflect the subject's perception of treatment effects and drive retreatment decisions
- Proportion of subjects mostly satisfied or very satisfied on FLSQ Item 5 (primary time
- Proportion of responders on FLSQ Impact Domain, defined by a ≥20-point
- improvement from baseline (primary time point: day 30)

 Proportion of responders on FLO-11 Item 4, defined by a ≥3-point improvement
- from baseline (primary time point: day 30) for subjects with baseline scores ≤80 These PRO measures were evaluated in the intent-to-treat (ITT) population, consisting
- of all randomized subjects Comparisons between the onabotulinumtoxinA groups versus placebo were conducted using the Cochran-Mantel-Haenszel test, strattfied by study site, with statistical significance achieved at Ps0.05

RESULTS

Subjects

 The ITT population comprised 787 subjects, including 313 in the onabotulinumtoxinA 64 U group, 318 in the onabotulinumtoxinA 40 U group, and 156 in the placebo group

- Overall, 728 subjects (92.5%) received a second treatment cycle and 510 subjects (64.8%) received a third treatment cycle during the open-label period
- The majority of subjects completed the study (n=684; 86.9%); discontinuations mostly due to being lost to follow-up (n=49: 6.2%) or personal reasons (n=44: 5.6%)
- Demographics and baseline characteristics were similar among treatment groups (Table 1) Table 1. Subject Demographics and Baseline Characteristics (ITT

Parameter	OnabotulinumtoxinA On 64 U (n=313)	nabotulinumtoxinA 40 U (n=318)	Placebo (n=156)
Age, mean, years	45.5	47.6	48.1
Range	21-76	22-75	22-73
Female, n (%)	284 (90.7)	278 (87.4)	140 (89.7)
Caucasian, n (%)	285 (91.1)	287 (90.3)	145 (92.9)
FHL severity at maximum	eyebrow elevation, subject F	WS rating, n (%)	
Moderate	162 (51.8)	171 (53.8)	82 (52.6)
Severe	151 (48.2)	147 (46.2)	74 (47.4)
GL severity at maximum to	frown, investigator FWS rating	g, n (%)*	
Moderate	119 (38.0)	101 (31.8)	49 (31.4)
Severe	194 (62.0)	217 (68.2)	106 (67.9)
CFL severity at maximum	smile, investigator FWS ratir	ng, n (%)	
Moderate	140 (45.0)	123 (38.8)	66 (42.9)
Severe	171 (55.0)	194 (61.2)	88 (57.1)
FLO-11 Item 4 score,† mean (range)	6.4 (0-10)	6.2 (0-10)	6.1 (0-10)
FLSQ Impact Domain score.* mean (range)	60.7 (5–100)	58.9 (0-100)	59.1 (15–100)

FLSQ Item 5

- The proportion of subjects who were mostly or very satisfied with onabotulinumtoxinA 64 U and 40 U was significantly greater than with placebo, respectively, on day 30 (89.8% and 82.0% vs 5.8%; both P<0.0001) and on day 60, the primary time point (87.9% and 81.4%
- Subject satisfaction with treatment remained significantly higher in both onabotulinumtoxinA groups compared with placebo at all time points through the end of the double-blind tment period (ie, day 180) (all, P<0.0001) (Figure 3)
- During the open-label period, subject satisfaction was maintained with repeated


onabotulinumtoxinA 64 U treatment, including in subjects initially allocated to placebo Figure 3. Subjects Mostly Satisfied or Very Satisfied on FLSQ Item 5



FLSQ Impact Domain

- · The responder rate on the FLSQ Impact Domain was significantly greater in the onabotulinumtoxinA 64 U and 40 U groups versus placebo on day 30 (76.1% and 61.0% vs 19.7%; both P<0.0001)
- The FLSQ Impact Domain responder rate remained significantly higher with nabotulinumtoxinA 64 U (all P<0.0001) and 40 U (P≤0.0009) versus placebo at all time points through day 180 (Figure 4) During the open-label treatment period ELSO Impact Domain responder rates were
- erally maintained with repeated onabotulinumtoxinA 64 U treatment (Figure 4)

Figure 4. Responders Reporting ≥20-Point Improvement From Baseline on FLSQ Impact Domain During the Entire 12-Month Study (Subjects With Baseline Score >20)




FLO-11 Item 4

- The responder rate on ELO-11 Item 4 (looking older than actual age) was significantly greater in the onabotulinumtoxinA 64 U and 40 U groups versus placebo on day 30 (77.1 and 66.7% vs 9.9%; both P<0.0001)
- The ELO-11 Item 4 responder rate remained significantly higher with onabotulinumtoxinA 64 U and 40 U versus placebo at all time points through day 180 (Ps0.0001) (Figure 5)

 Like the other PRO measures, the FLO-11 responder rate was generally maintained with repeated onabotulinumtoxinA 64 U treatment during the open-label period (Figure 5)

Figure 5, Responders Reporting ≥3-Point Improvement From Baseline FLO-11 Item 4 During the Entire 12-Month Study (Subjects With



CONCLUSIONS

Subjects were highly satisfied with onabotulinumtoxinA 64 U treatment of UFL (FHL, GL, and CFL) and with onabotulinumtoxinA 40 U treatment of

- With both onabotulinumtoxinA regimens, subjects reported significant improvements in appearance-related and emotional impacts of their
- a single treatment cycle, and were maintained thereafter with repeated onabotulinumtoxinA treatment

REFERENCES

- Finn CJ, et al. Dermatol Surg. 2003;29(5):450-5.
 Cox SE, Finn JC. Int Ophthalmol Clin. 2005;45(3):13-24.
- Gupta MA, Gilchrest BA. Dermatol Clin. 2005;23(4):643-8.
- Carruthers JD, Carruthers JA. J Dermatol Surg Oncol. 1992;18(1):17-21.
- 5 Carruthers I et al. Dermatol Sum. 2015;41(6):702-11
- Lorenc ZP, et al. Aesthet Surg J. 2013;33(1 Suppl):35S-40S.
- Carruthers J. Carruthers A. Dermatol Surg. 2007;33(1 Spec No.):S10-S7. Michaels BM, et al. Aesthet Surg J. 2012;32(1):96-102.
- 9. de Boulle K, et al. Presented at: International Master Course on Aging Sciences; February 1-3, 2017; Paris, France,
- Pompilus F, et al. J Cosmet Dermatol. 2015;14(4):274-85.
- 11 Yaworsky A et al. J Cosmet Dermetol. 2014:13(4):297-306

ACKNOWLEDGMENTS

This study was sponsored by Allergan plc, Dublin, Ireland. Medical writing and editorial as was provided to the authors by Cactus Communications and was funded by Allergan plc. 4 met the ICAMIE authorship criteria. Neither honoraria nor other form of payments were man

FINANCIAL DISCLOSURES

S Dayan has received research support or speaking/consultant fees from Allergan plc, Galderma Subgrain as received research support on a pseuding-constant nees instrumental in its constant and investigator for Allergan pic. AZ Rivkin serves as a consultant and investigator for Allergan pic and Merz Aesthetics. SG Yoelin serves as a consultant and investigator for Allergan pic a Merz Aesthetics. SG Yoelin serves as a consultant and investigator for Allergan pic at Merz Aesthetics. SG Yoelin serves as a consultant and investigator for Allergan pic at Merz Aesthetics. SG Yoelin serves as a consultant and investigator for Allergan pic at Merz Aesthetics. SG Yoelin serves as a consultant and investigator for Allergan pic at Merz Aesthetics. SG Yoelin serves as a consultant and investigator for Allergan pic and may own stockloptions in the company. It Ferrusi was an employee of Allergan pic at the time of this study.

